Way GP, Kost-Alimova M, Shibue T, et al. Predicting cell health phenotypes using image-based morphology profiling. Mol Biol Cell. 2021;32(9):995-1005. doi:10.1091/mbc.E20-12-0784Google ScholarDOIPubMed
Carlos Slim Center for Health Research
Dharia NV, Kugener G, Guenther LM, et al. A first-generation pediatric cancer dependency map. Nat Genet. 2021;53(4):529-538. doi:10.1038/s41588-021-00819-wGoogle ScholarDOIPubMed
Neggers JE, Paolella BR, Asfaw A, et al. Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. Cell Rep. 2020;33(11):108493. doi:10.1016/j.celrep.2020.108493Google ScholarDOIPubMed
Kost-Alimova M, Sidhom EH, Satyam A, et al. A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury. Cell Rep Med. 2020;1(8):100137. doi:10.1016/j.xcrm.2020.100137Google ScholarDOIPubMed
Subramanian A, Sidhom EH, Emani M, et al. Single cell census of human kidney organoids shows reproducibility and diminished off-target cells after transplantation. Nat Commun. 2019;10(1):5462. doi:10.1038/s41467-019-13382-0Google ScholarDOIPubMed
Stover EH, Baco MB, Cohen O, et al. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer. Mol Cancer Res. 2019;17(11):2281-2293. doi:10.1158/1541-7786.MCR-18-1243Google ScholarDOIPubMed
Dvela-Levitt M, Kost-Alimova M, Emani M, et al. Small Molecule Targets TMED9 and Promotes Lysosomal Degradation to Reverse Proteinopathy. Cell. 2019;178(3):521-535.e23. doi:10.1016/j.cell.2019.07.002Google ScholarDOIPubMed
Flannick J, Mercader JM, Fuchsberger C, et al. Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls. Nature. 2019;570(7759):71-76. doi:10.1038/s41586-019-1231-2Google ScholarDOIPubMed
Price C, Gill S, Ho ZV, et al. Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers. Cancer Res. 2019;79(10):2564-2579. doi:10.1158/0008-5472.CAN-18-2674Google ScholarDOIPubMed
Hayes TK, Luo F, Cohen O, et al. A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma. Cancer Res. 2019;79(9):2352-2366. doi:10.1158/0008-5472.CAN-18-2711Google ScholarDOIPubMed